Talphera, Inc.
TLPHHealthcare|Drug Manufacturers - Specialty & Generic|US
$1.05
+0.04 (+3.96%)
Tangible Book / Share
$0.19
Cash / Share
$0.23
Clinical Trials (18)
| Trial | Conditions | Phase | Status | Enrollment | Design | Drug |
|---|---|---|---|---|---|---|
| NCT02447848 Open-Label Safety and Efficacy of the Sufentanil Sublingual Tablet 30 mcg for Acute Pain | Moderate-to-severe Acute Pain | P3 | Completed | 76 | Open-label | sufentanil sublingual 30 mcg tablet |
| NCT01539642 A Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial to Evaluate the Efficacy and Safety of the Sufentanil NanoTab PCA System/15 mcg (Zalviso™) for the Treatment of Post-Operative Pain in Patients After Open Abdominal Surgery | Post-Operative Pain | P3 | Completed | 172 | RCT, Double-blind | Sufentanil NanoTab PCA System/15 mcg, Placebo Sufentanil NanoTab PCA System |
| NCT01539538 A Multicenter, Randomized, Open-Label, Parallel-Group Trial to Compare the Efficacy and Safety of the Sufentanil NanoTab PCA System/15 mcg (Zalviso™)to Intravenous Patient-Controlled Analgesia With Morphine for the Treatment of Acute Post-Operative Pain | Post-Operative Pain | P3 | Completed | 357 | RCT, Open-label | Sufentanil NanoTab PCA System/15 mcg, morphine IV PCA |
| NCT01660763 Efficacy and Safety Trial to Evaluate the Sufentanil NanoTab® PCA System/15 mcg (Zalviso™) for Post-Operative Pain in Patients After Knee or Hip Replacement Surgery | Post Operative Pain | P3 | Completed | 419 | RCT, Double-blind | Sufentanil NanoTab PCA System/15 mcg, Placebo Sufentanil NanoTab PCA System |
| NCT02356588 A Trial Evaluating the Efficacy and Safety of the Sublingual Sufentanil Tablet 30 mcg for Post-Operative Pain After Abdominal Surgery | Post-Operative Pain | P3 | Completed | 161 | RCT, Double-blind | Sufentanil Tablet 30 mcg, Placebo Tablet |
| NCT02662556 A Multicenter, Open-Label Trial to Evaluate the Safety and Efficacy of the Sufentanil Sublingual Tablet 30 mcg in Patients With Post-Operative Pain | Acute Moderate-to-severe Pain | P3 | Completed | 140 | Open-label | sufentanil sublingual tablet 30 mcg |
| NCT02662764 Study to Evaluate the Overall Performance of the Zalviso System™ (Sufentanil Sublingual Tablet System) 15 mcg | Moderate-to-severe Acute Pain | P3 | Completed | 320 | Open-label | Zalviso™ 15 mcg |
| NCT01710345 Safety and Efficacy of Sufentanil NanoTab for Management of Acute Pain Following Bunionectomy | Acute Pain | P2 | Completed | 101 | RCT, Double-blind | Sufentanil NanoTab 20 mcg, Sufentanil NanoTab 30 mcg, Placebo NanoTab |
| NCT00859313 An Open-Label Functionality, Safety and Efficacy Study in Patients Undergoing Elective Unilateral Knee Replacement | Pain, Postoperative | P2 | Completed | 30 | Open-label | Sufentanil NanoTab PCA System/15 mcg |
| NCT00894699 A Study to Evaluate the Clinical Efficacy, Safety and Tolerability of ARX-F03 Sublingual Sufentanil/Triazolam NanoTab™ in Patients Undergoing an Elective Abdominal Liposuction Procedure | Sedation, Anxiety | P2 | Completed | 40 | RCT, Double-blind | Sublingual Sufentanil/Triazolam NanoTab™ (ARX-F03), Placebo NanoTab™ |
| NCT00833040 A Study for the Evaluation of the Safety, Tolerability, and Efficacy of ARX-F02 (Sufentanil NanoTab) Compared to Placebo in the Treatment of Cancer Breakthrough Pain | Cancer, Pain | P2 | Completed | 34 | RCT, Double-blind | Sublingual sufentanil NanoTabs™ and placebo NanoTabs™ |
| NCT00718081 A Multicenter, Randomized, Placebo-Controlled Phase 2 Study to Evaluate the Clinical Efficacy, Safety, and Tolerability of ARX-F01 Sublingual Sufentanil in Patients Undergoing Major Abdominal Surgery | Major Upper or Lower Abdominal Surgery | P2 | Completed | 88 | RCT, Double-blind | Oral sufentanil, Placebo |
| NCT00612534 A Multicenter, Randomized, Placebo-Controlled Phase 2 Study to Evaluate the Clinical Efficacy, Safety, and Tolerability of ARX-F01 Sublingual Sufentanil in Patients Undergoing Elective Unilateral Total Knee Replacement | Post Operative Pain | P2 | Completed | 94 | RCT, Double-blind | Sufentanil NanoTab, Placebo NanoTab, Sufentanil NanoTab, Sufentanil NanoTab |
| NCT01721070 Effect of Ketoconazole on Sufentanil NanoTab Pharmacokinetics | Pharmacokinetics | P1 | Completed | 19 | Open-label | Sufentanil NanoTab (SUF NT) 15 mcg, Ketoconazole 400 mg, sufentanil NanoTab (SUF NT) 15 mcg |
| NCT01761565 Single and Multiple Dose Pharmacokinetics of Sufentanil NanoTab | Plasma Concentrations | P1 | Completed | 40 | Open-label | Single dose of SUF NT 15 mcg, 40 consecutive doses of SUF NT 15 mcg taken every 20 minutes |
| NCT01639729 Effect of Delivery Route on PK of Sufentanil NanoTab | Pharmacokinetics | P1 | Completed | 25 | RCT, Open-label | Treatment A: Sufentanil IV, Treatment B: Sufentanil NanoTab Sublingual, Treatment C: Sufentanil NanoTab Buccal, Treatment D: Sufentanil NanoTab Oral |
| NCT02082236 Pharmacokinetics of Sufentanil Sublingual Microtablet 30 mcg and 15 mcg in Healthy Subjects | Healthy | P1 | Completed | 40 | RCT, Open-label | Treatment Arm A: Sufenta®, Treatment B: Sufentanil SSM 30 mcg, Treatment C: SSM 15 mcg, Treatment D: SSM 30 mcg |
| NCT06150742 Nafamostat Efficacy in Phase 3 Registrational CRRT Study | Acute Kidney Injury | N/A | Unknown | 70 | RCT, Double-blind | — |